David Kandzari reviews the Spyral-HTN On study results for control of hypertension using renal denervation
SPYRAL HTN-ON MED confirmed RDN’s blood pressure lowering effect, in patients prescribed BP medications, at 6-months1
- 24-hour systolic ambulatory blood pressure (ABPM) decreased 9.0 mmHg in...
SPYRAL HTN-ON MED confirmed RDN’s blood pressure lowering effect, in patients prescribed BP medications, at 6-months1
- 24-hour systolic ambulatory blood pressure (ABPM) decreased 9.0 mmHg in RDN patients (P<0.0001)
- Office systolic blood pressure (OSBP) decreased 9.4 mmHg in RDN patients (P<0.0001)
- RDN is always on and provides 24-hr blood pressure lowering, including during “high-risk” periods2,3,4
- RDN procedures with the Symplicity SpyralTM system continued to be safe, despite a more rigorous approach1 Zero major adverse events at 6-months
- Ablations were performed in the renal branch and accessory arteries, as well as main renal artery
- In previous research, BP reductions of the magnitude reported in SPYRAL HTN-ON MED have been associated with a >20% relative risk reduction of cardiovascular events5
- The SPYRAL HTN Global Clinical Program continues with the ongoing OFF MED pivotal trial
Footnotes/References:
1Kandzari et al, PCR 2018
2The HTN-ON med 24-hr data showed that BP was reduced throughout the day and night at a 6-month endpoint
3Amodeo C, Blood Pressure Monit, 2014
4Boggia J, The Lancet, 2007
5Ettehad D et al., The Lancet, 2016
Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation...
Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation as an adjunctive therapy for treating Hypertension.
It answers frequently asked questions with the latest expert opinions, guideline summaries, and essential information for practical adoption in managing uncontrolled and resistant Hypertension.
Learn about patient selection, key evidence for safety, effectiveness, durability, and integrating Renal Denervation into your practice.
Supported by an educational grant from Medtronic.
Speakers
David Kandzari
Speaker
Dr. David E. Kandzari is the Chief of the Piedmont Heart Institute and Cardiovascular Service... Dr. David E. Kandzari is the Chief of the Piedmont Heart Institute and Cardiovascular Service Line; Director, Interventional Cardiology of the Piedmont Heart Institute; and Chief Scientific Officer for Piedmont Healthcare in Atlanta, Georgia. Dr. Kandzari specializes in cardiovascular disease, peripheral arterial disease and interventional cardiology. A graduate of Duke University School of Medicine, he completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences. Dr. Kandzari is the former Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as Chief Medical Officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a Medical Officer for the Center for Devices and Radiological Health for the United States Food and Drug Administration. Board certified by the American Board of Internal Medicine and its subspecialty Board of Cardiovascular Disease and Board of Interventional Cardiology, Dr. Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 400 studies, book chapters and scientific reviews, and has delivered more than 700 lectures, both nationally and internationally, on a variety of issues related to both interventional and general cardiology. Dr. Kandzari has been consecutively voted as one of Atlanta's Top Doctors by Atlanta Magazine from 2011 to 2021, and is peer-nominated in the top 1% of cardiologists by U.S News and World Report.
